| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1950319 | Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids | 2007 | 12 Pages |
Abstract
Agonists of PPARα and PPARγ are currently approved for use in treating, respectively, dyslipidemia and type 2 diabetes. Agonists of PPARβ/δ are currently in development by several pharmaceutical companies. Despite their therapeutic importance, there are dose limiting side effects associated with PPAR drug treatments, thus a new generation of safer PPAR drugs are being actively sought after. In this review we will discuss the side effects associated the PPARs, how the current drugs in clinical development were discovered and new concepts in how to screen for PPAR drugs.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry
Authors
Barry G. Shearer, Andrew N. Billin,